Monograph Details
|
|
Cardiovascular System
> Hypertension
|
|
TIAZAC |
| Manufacturer |
|
Forest Laboratories |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Calcium channel blocker (benzothiazepine). |
| Generic Name |
|
Diltiazem HCl 120mg, 180mg, 240mg, 300mg, 360mg, 420mg; ext rel beads in caps. |
| Indications |
|
Hypertension. |
| Children |
|
Not recommended. |
| Adults |
|
May sprinkle contents on applesauce; do not crush or chew contents. Initially 120–240mg once daily; adjust at 2-week intervals; usual max 540mg/day. |
| Contraindications |
|
Sick sinus syndrome, 2nd- or 3rd-degree AV block, unless paced. Severe hypotension. Acute MI and pulmonary congestion documented by X-ray on admission. |
| Precautions |
|
Heart failure. Impaired renal or hepatic function. Monitor liver function. Discontinue if persistent rash occurs. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Digoxin and β-blockers may lead to AV block. Serum propranolol, carbamazepine levels may be increased. Potentiation with cimetidine. Monitor digoxin, cyclosporine. Anesthetics may potentiate cardiac depression. |
| Adverse Reactions |
|
Edema, headache, dizziness, asthenia, 1st-degree AV block, bradycardia, flushing, nausea, rash; CHF, liver abnormalities (rare). |
| How Supplied |
|
Caps—30, 90, 1000 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
